<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005313" GROUP_ID="VASC" ID="732004011315431940" MERGED_FROM="" MODIFIED="2012-11-26 15:58:13 +0000" MODIFIED_BY="Diane Horsley" NOTES="&lt;p&gt;Exported from Review Manager 4.2.6&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-11-26 15:58:13 +0000" NOTES_MODIFIED_BY="Diane Horsley" REVIEW_NO="9932" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-11-26 15:56:14 +0000" MODIFIED_BY="Diane Horsley">
<TITLE>Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction</TITLE>
<CONTACT>
<PERSON ID="15780" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alain</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Nordmann</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ANordmann@uhbs.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel</ORGANISATION>
<ADDRESS_1>Hebelstrasse 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+ 41 76 470 34 13</PHONE_1>
<PHONE_2/>
<FAX_1>+41 61 265 31 09</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-11-26 15:53:27 +0000" MODIFIED_BY="Diane Horsley">
<PERSON ID="15780" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alain</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Nordmann</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ANordmann@uhbs.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel</ORGANISATION>
<ADDRESS_1>Hebelstrasse 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+ 41 76 470 34 13</PHONE_1>
<PHONE_2/>
<FAX_1>+41 61 265 31 09</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18834" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Heiner</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Bucher</LAST_NAME>
<SUFFIX>MD MPH</SUFFIX>
<POSITION/>
<EMAIL_1>hbucher@uhbs.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute for Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>University Hospital Basel</ORGANISATION>
<ADDRESS_1>Petersgraben 4</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>CH-4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 61 265 2525</PHONE_1>
<PHONE_2/>
<FAX_1>+41 61 265 4300</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19078" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>P</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hengstler</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>no Roles</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medizinische Universitäts-Poliklinik</DEPARTMENT>
<ORGANISATION>Kantonsspital Basel</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>CH-4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D44B952D82E26AA20078D4E6FFC75153" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Harr</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Dermatology</DEPARTMENT>
<ORGANISATION>University Hospital Basel</ORGANISATION>
<ADDRESS_1>Petersgraben 4</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 61 265 2525</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16059A7782E26AA2007AE038B3AC07C1" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Young</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jyoung@uhbs.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Basel Institute for Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>University Hospital Basel</ORGANISATION>
<ADDRESS_1>Hebelstrasse 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Basel</CITY>
<ZIP>4031</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 61 265 3100</PHONE_1>
<PHONE_2/>
<FAX_1>+41 61 265 3109</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-11-26 15:56:14 +0000" MODIFIED_BY="Liz Bickerdike" NOTES="&lt;p&gt;Minor update: 15/08/05&lt;/p&gt;" NOTES_MODIFIED="2012-11-26 15:56:14 +0000" NOTES_MODIFIED_BY="Liz Bickerdike">
<UP_TO_DATE>
<DATE DAY="1" MONTH="2" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="2" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-26 15:56:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update Issue 4 2005, August &lt;br&gt;&lt;br&gt;The data for the Grines study and the Jaksch study for 6 month mortality were transposed.  This error is now corrected. &lt;br&gt;&lt;br&gt;Grines CL, Cox DA, Stone GW et al. 1999. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. New England Journal of Medicine. 1999;341;26; 1949-56.&lt;br&gt;&lt;br&gt;Jaksch R, Niehus R, Knobloch W, Schiele T. PTCA versus stenting in acute myocardial infarction. European Heart Journal. 1998;19;239;1341. &lt;br&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-11-26 15:56:05 +0000" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2012-11-26 15:56:05 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>This review is no longer being updated as stenting has replaced balloon angioplasty as a treatment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-11-26 15:54:29 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-26 15:54:29 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Basel Institute for Clinical Epidemiology</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Medical Outpatient Clinic, University Hospital Basel</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-11-26 15:58:13 +0000" MODIFIED_BY="Karen Hovhannisyan">
<SUMMARY MODIFIED="2008-09-09 10:15:24 +0100" MODIFIED_BY="Karen Hovhannisyan">
<TITLE MODIFIED="2008-09-09 10:15:24 +0100" MODIFIED_BY="Karen Hovhannisyan">In people who have had a heart attack because of blocked heart arteries insertion of thin metal tubes (stents) were better than using small balloons to open the arteries up again</TITLE>
<SUMMARY_BODY>
<P>Arteries can become clogged and narrowed with deposits of fat, cholesterol and other substances. This is called atherosclerosis and can cause heart attack. Two methods to open narrowed or clogged arteries in people who have had a recent heart attack are inserting a deflated small balloon in the artery and expand it to open the vessel (balloon angioplasty) or to insert a thin metal tube or sleeve (stent) into the artery to scaffold the artery open. This review compared these treatments and found both were equally effective at preventing death but using stents was better than balloon angioplasty because fewer arteries needed to be re-cleared and stents prevented more heart attacks than balloon angioplasty. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Balloon angioplasty following myocardial infarction (MI) reduces death, non-fatal MI and stroke compared to thrombolytic reperfusion. However up to 50% of patients experience restenosis and 3% to 5% recurrent myocardial infarction. Therefore, primary stenting may offer additional benefits compared to balloon angioplasty in patients with acute myocardial infarction.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine whether primary stenting compared to primary balloon angioplasty reduces clinical outcomes in patients with acute myocardial infarction. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched MEDLINE, EMBASE, Pascal, Index medicus and The Cochrane Controlled Trials Register (The Cochrane Library) from 1979 to March 2002.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of primary stenting or balloon angioplasty prior to the invasive procedure; intervention in native coronary arteries within 24 hours after onset of symptoms of myocardial infarction; report of death or reinfarction; and follow-up of at least 1 month. Trials were excluded when randomisation occurred after an invasive procedure and if they exclusively included patients with cardiogenic shock. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently selected and extracted data from identified trials. Outcomes included mortality, reinfarction, coronary artery bypass grafting, target vessel revascularization, need for vascular repair or blood transfusion. Peto odds ratios were calculated. To explore the stability of the overall treatment effect various sensitivity analyses were performed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included nine trials of 4433 participants. Odds ratios for mortality after stenting compared to balloon angioplasty at 30 days, 6 and 12 months were 1.16 (95% CI 0.78 to 1.73), 1.27 (95% CI 0.89 to 1.83), and 1.06 (95% CI 0.77 to 1.45). At 30 days, 6 and 12 months odds ratios for reinfarction after stenting compared to balloon angioplasty were 0.52 (95% CI 0.31 to 0.87), 0.67 (95% CI 0.45 to 1.00), and 0.67 (95% CI 0.45-0.98) and odds ratio for target vessel revascularization after stenting compared to balloon angioplasty were 0.45 (95%CI 0.34 to 0.60), 0.42 (95% CI 0.35 to 0.51), and 0.47 (95% CI 0.38 to 0.57). The odds ratio for post-interventional bleeding complications after stenting compared to balloon angioplasty was 1.34 (95% CI 0.95 to 1.88; test of heterogeneity p &gt; 0.1).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is no evidence to suggest that primary stenting reduces mortality when compared to balloon angioplasty. Stenting seems to be associated with a reduced risk of reinfarction and target vessel revascularization, but potential confounding due to unbalanced post-interventional antithrombotic/anticoagulant therapies can not be ruled out on basis of this review.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>In patients with acute myocardial infarction balloon angioplasty reduces short-term death, non-fatal myocardial infarction and stroke when compared to thrombolytic reperfusion (<LINK REF="REF-Keeley-2003" TYPE="REFERENCE">Keeley 2003</LINK>). However, the clinical efficacy of balloon angioplasty for acute myocardial infarction is limited by late restenosis in up to 50% of patients, and by recurrent myocardial infarction in 3 to 5 percent of patients (<LINK REF="REF-de-Boer-1995" TYPE="REFERENCE">de Boer 1995</LINK>; <LINK REF="REF-Nunn-1999" TYPE="REFERENCE">Nunn 1999</LINK>; <LINK REF="REF-Stone-1995" TYPE="REFERENCE">Stone 1995</LINK>; <LINK REF="REF-Stone-1997" TYPE="REFERENCE">Stone 1997</LINK>). Therefore, primary stenting may offer additional benefits compared to balloon angioplasty in patients with acute myocardial infarction. A recent meta-analysis of clinical trials comparing primary stenting with balloon angioplasty in acute myocardial infarction found no difference in mortality and reinfarction rates (<LINK REF="REF-Zhu-2001" TYPE="REFERENCE">Zhu 2001</LINK>). This systematic review, however, includes additional preliminary data from trials that have not been published in detail yet. </P>
<P>We conducted a meta-analysis based on published and unpublished trial data to investigate whether primary stenting compared to balloon angioplasty reduces mortality, recurrent events and the risk of bleeding in patients with acute myocardial infarction. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine whether primary stenting compared to primary balloon angioplasty reduces clinical outcomes in patients with acute myocardial infarction. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with acute myocardial infarction. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Trials were included if they met the following criteria: randomisation to primary stenting or balloon angioplasty prior to the invasive procedure, intervention in native coronary arteries within 24 hours after onset of symptoms of acute myocardial infarction, report of death or reinfarction, and follow-up of at least one month. We excluded trials where patients were randomised after balloon angioplasty had already been performed and trials that exclusively included patients in cardiogenic shock.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The main outcome of interest was mortality at 30 days, 6 and 12 months of follow-up. Other endpoints were reinfarction, coronary artery bypass grafting (CABG), target vessel revascularization, and a composite outcome of death and reinfarction at 30 days, 6 and 12 months after the intervention as well as procedure-related bleeding complications (defined as bleedings with need for vascular repair or blood transfusion, retroperitoneal, intracerebral or fatal bleedings).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We searched MEDLINE, EMBASE, Pascal, Index medicus, The Cochrane Controlled Trials Register (<I>The Cochrane Library)</I> and abstracts from cardiology conferences from 1979 to March 2002 to identify all randomised controlled trials comparing primary stenting with balloon angioplasty in patients with acute myocardial infarction. </P>
<P>We used the following search terms: </P>
<P>Angioplasty-transluminal-percutaneous-coronary#, <BR/>Stents#, <BR/>Randomised-controlled-trials#, <BR/>Clinical-trials#, <BR/>Coronary-artery-dilatation#, <BR/>Transluminal-coronary-angioplasty#, <BR/>Random#. </P>
<P>In addition, we searched all references of relevant articles for additional trials and if necessary, contacted authors of identified trials to ask for additional information.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of references to publications of interest</B>
<U>
<BR/>
</U>Two reviewers independently selected the relevant trials and resolved disagreement by consensus. The same reviewers extracted data from all trials that fulfilled inclusion criteria.<BR/>
<B>
<BR/>Assessment of trial quality</B>
<U>
<BR/>
</U>Two reviewers independently assessed the quality of each included trial and summarized the quality of each trial using a modified Jadad score (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). We rated the methodologic quality of the included trials based on the following items: 1) randomisation of participants, 2) blinding of patients, caregivers, and those assessing outcome 3) full description of withdrawals and drop outs. The scoring gives one point to each item if present. If randomisation is concealed, and if the method of double blinding is appropriate the study receives one additional point each, thus yielding a score with a range from 0 to 5 points. Agreement between the two reviewers was assessed by calculating proportions of specific agreement for positive and negative ratings (<LINK REF="REF-Cicchetti-1990" TYPE="REFERENCE">Cicchetti 1990</LINK>). Disagreement between reviewers was resolved by consensus.</P>
<P>
<B>Examination of publication bias</B>
<U>
<BR/>
</U>We used a plot of standardized effect against precision to test for the presence of publication bias (funnel plot) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). </P>
<P>
<B>Data aggregation and sensitivity analysis</B>
<U>
<BR/>
</U>We used <LINK REF="REF-RevMan-Analyses" TYPE="REFERENCE">RevMan Analyses</LINK> statistical software to calculate Peto's odds ratios for the primary and secondary outcomes (<LINK REF="REF-Deeks-1998" TYPE="REFERENCE">Deeks 1998</LINK>) To explore the stability of the overall treatment effect, we compared trials using different stent types, trials using different post-interventional antithrombotic / anticoagulant drug therapies, and trials with a crossover rate from balloon angioplasty to stenting below and above the median (cross-over rate of 15%). In addition, we compared trials reporting concealed randomisation with trials not reporting concealed randomisation, trials reporting blinded outcome assessment with trials not reporting blinded outcome assessment, and repeated analyses after excluding results of unpublished trials. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>We identified 603 references of interest. O the references with potential for inclusion 53 references to 47 studies were excluded <I>(See Table of Excluded studies)</I>. 9 studies (10 references) met our inclusion criteria (<LINK REF="STD-GRAMI" TYPE="STUDY">GRAMI</LINK>; <LINK REF="STD-Grines" TYPE="STUDY">Grines</LINK>; <LINK REF="STD-Jaksch" TYPE="STUDY">Jaksch</LINK>; <LINK REF="STD-PASTA" TYPE="STUDY">PASTA</LINK>; <LINK REF="STD-PRISAM" TYPE="STUDY">PRISAM</LINK>; <LINK REF="STD-Scheller" TYPE="STUDY">Scheller</LINK>; <LINK REF="STD-STENTIM_x002d_2" TYPE="STUDY">STENTIM-2</LINK>; <LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>; <LINK REF="STD-Suryapranata" TYPE="STUDY">Suryapranata</LINK>. Two citations were identified that referred to one trial and described outcomes and long-term follow-up results (<LINK REF="STD-Suryapranata" TYPE="STUDY">Suryapranata</LINK>). We did not include one trial where patients were randomised to provisional stenting or optimal balloon angioplasty because in this trial patients were randomised after balloon angioplasty had already been performed (<LINK REF="REF-Antoniucci-1998" TYPE="REFERENCE">Antoniucci 1998</LINK>). Thus, nine trials with a total of 4433 patients were included in our meta-analysis <I>(See Characteristics of included studies tables)</I>. Five of these trials explicitly excluded patients with cardiogenic shock. Two trials allowed for the inclusion of patients with cardiogenic shock: 8 out of 104 patients in the GRAMI trial and 6 out of 44 patients in the PSAAMI trial were in cardiogenic shock at inclusion (<LINK REF="STD-GRAMI" TYPE="STUDY">GRAMI</LINK>; <LINK REF="STD-Scheller" TYPE="STUDY">Scheller</LINK>).</P>
<P>Routine use of abciximab was only foreseen in the study protocol of the CADILLAC trial (<LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>). The CADILLAC-trial had a 2 by 2 factorial design and randomised patients to either balloon angioplasty alone, balloon angioplasty plus abciximab, stenting alone or stenting plus abciximab. In our primary analysis we compared all patients randomised to balloon angioplasty (with or without abciximab) with all patients randomised to stenting (with or without abciximab). </P>
<P>Palmaz-Schatz stents were used in three trials (<LINK REF="STD-Grines" TYPE="STUDY">Grines</LINK>; <LINK REF="STD-PASTA" TYPE="STUDY">PASTA</LINK>; <LINK REF="STD-Suryapranata" TYPE="STUDY">Suryapranata</LINK>); one of them used a heparin-coated stent (<LINK REF="STD-Grines" TYPE="STUDY">Grines</LINK>). Two trials used Wiktor stents (<LINK REF="STD-PRISAM" TYPE="STUDY">PRISAM</LINK>; <LINK REF="STD-STENTIM_x002d_2" TYPE="STUDY">STENTIM-2</LINK>). The remaining trials used various other types of stents (<LINK REF="STD-GRAMI" TYPE="STUDY">GRAMI</LINK>; <LINK REF="STD-Jaksch" TYPE="STUDY">Jaksch</LINK>; <LINK REF="STD-Scheller" TYPE="STUDY">Scheller</LINK>; <LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>). </P>
<P>All trials used more aggressive post-interventional antithrombotic / anticoagulant therapies in patients assigned to stenting. Patients treated with stents were given aspirin and either ticlopidine, clopidogrel or warfarin, whereas patients treated with balloon angioplasty were generally only given aspirin. In the CADILLAC trial all patients randomised to stenting and approximately 50% of patients randomised to PTCA received either ticlopidine or clopidogrel (<LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>).</P>
<P>
<B>Agreement on Quality Rating</B>
<BR/>There was complete agreement between both reviewers for concealment of treatment allocation, and full description of follow-up. For blinded outcome assessment, proportions of specific agreement were 0.80 for positive ratings and 0.92 for negative ratings. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Random allocation was concealed in 4 trials (<LINK REF="STD-Grines" TYPE="STUDY">Grines</LINK>; <LINK REF="STD-Scheller" TYPE="STUDY">Scheller</LINK>; <LINK REF="STD-STENTIM_x002d_2" TYPE="STUDY">STENTIM-2</LINK>; <LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>) and possibly concealed in the remaining 5 trials (<LINK REF="STD-GRAMI" TYPE="STUDY">GRAMI</LINK>; <LINK REF="STD-Jaksch" TYPE="STUDY">Jaksch</LINK>; <LINK REF="STD-PASTA" TYPE="STUDY">PASTA</LINK>; <LINK REF="STD-PRISAM" TYPE="STUDY">PRISAM</LINK>; <LINK REF="STD-Suryapranata" TYPE="STUDY">Suryapranata</LINK>). Blinded outcome assessment of clinical endpoints was reported only in three trials (<LINK REF="STD-Grines" TYPE="STUDY">Grines</LINK>; <LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>; <LINK REF="STD-Suryapranata" TYPE="STUDY">Suryapranata</LINK>). In three trials (<LINK REF="STD-Grines" TYPE="STUDY">Grines</LINK>; <LINK REF="STD-Jaksch" TYPE="STUDY">Jaksch</LINK>; <LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>) description of follow-up and withdrawals was incomplete. See Table of Included studies.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Clinical Outcomes</B>
<BR/>
<B>
<I>Mortality (comparison 01, outcome 01, 02, 03). </I>
</B>
<BR/>Odds ratios for mortality at 30 days, 6 and 12 months after primary stenting compared to balloon angioplasty were 1.16 (95% Confidence Interval (CI) 0.78 to 1.73), 1.27 (95% CI 0.89 to 1.83), and 1.06 (95% CI 0.77 to 1.45). Although the point estimates indicated harm from primary stenting, they were not statistically significant as indicated by the 95% confidence intervals. There was no evidence of heterogeneity for all three estimates (p &gt; 0.1). </P>
<P>
<B>
<I>Reinfarction (comparison 02, outcome 01, 02, 03). </I>
</B>
<BR/>Odds ratios for reinfarction after primary stenting compared to balloon angioplasty at 30 days, 6 and 12 months were 0.52 (95% CI 0.31 to 0.87), 0.67 (95% CI 0.45-1.00), and 0.67 (95% CI 0.45 to 0.98). There was some evidence of heterogeneity (p &gt; 0.1) for reinfarction at 12 months, p=0.08.</P>
<P>
<B>
<I>Target vessel revascularisation (comparison 03, outcome 01, 02, 03). </I>
<BR/>
</B>Odds ratio for target vessel revascularization after primary stenting compared to balloon angioplasty at 30 days, 6 and 12 months were 0.45 (95% CI 0.34 to 0.60), 0.42 (95% CI 0.35 to 0.51) and 0.47 (95% CI 0.38 to 0.57). </P>
<P>
<B>
<I>Coronary artery bypass grafting</I>
</B>
<U>
<BR/>
</U>Odds ratios for coronary artery bypass grafting and the composite endpoint of reinfarction and death after primary stenting compared to balloon angioplasty were not statistically significant. </P>
<P>
<B>
<I>Post interventional bleeding<BR/>
</I>
</B>The odds ratio for post-interventional bleeding complications after primary stenting compared to balloon angioplasty was 1.34 (95% CI 0.95 to 1.88, test of heterogeneity p &gt; 0.1). </P>
<P>
<B>Sensitivity Analyses</B>
<BR/>
<B>
<I>Stent type </I>
</B>
<BR/>In trials using Palmaz-Schatz stents odds ratios for 30 days, 6 and 12 months mortality after primary stenting compared to balloon angioplasty were 1.27 (95% CI 0.65 to 2.45), 1.21 (95% CI 0.66 to 2.25), and 1.35 (95% CI 0.79 to 2.31) , and ) in trials using other types of stents 1.11 (95% CI 0.67 to 1.83), 1.01 (95% CI 0.66 to 1.52), and 0.97 (95% CI 0.66 to 1.44) (tests of heterogeneity for all comparisons p &gt; 0.1). </P>
<P>
<B>
<I>Post intervention anti-thrombotics therapies</I>
</B>
<U>
<BR/>
</U>Since all trials used more potent post-interventional antithrombotic therapies in patients treated with stenting a sensitivity analysis for this pre-specified criteria was not possible. In order to control for a potential treatment interaction of abciximab, we repeated our analysis and excluded all patients treated with abciximab from the CADILLAC trial (<LINK REF="STD-Stone" TYPE="STUDY">Stone</LINK>). When excluding patients treated with abciximab, the odds ratios for mortality after primary stenting compared to balloon angioplasty at 30 days, 6 and 12 months follow-up were 1.20 (95% CI 0.80 to 1.80), 0.91 (95% CI 0.61 to 1.36) and 1.04 (95% CI 0.69 to 1.56) (tests of heterogeneity for all comparisons p &gt; 0.1). </P>
<P>
<B>
<I>Cross over between treatment arms</I>
</B>
<U>
<BR/>
</U>In trials with lower crossover rates from balloon angioplasty to stenting (15%) odds ratios for 30 days, 6 and 12 months mortality after primary stenting compared to balloon angioplasty were 1.19 (95% CI 0.62 to 2.29), 1.21 (95% CI 0.66 to 2.21), and 1.35 (95% CI 0.79 to 2.31) as compared to 1.15 (95% CI 0.70 to 1.90), 1.01 (95% CI 0.66 to 1.55), and 0.97 (95% CI 0.66 to 1.44) in trials with crossover rates &gt; 15% (tests of heterogeneity for all comparisons p &gt; 0.1). </P>
<P>
<B>
<I>Concealment of treatment allocation</I>
</B>
<U>
<BR/>
</U>In trials reporting concealment of treatment allocation odds ratios for 30-days, 6 and 12 months mortality after primary stenting compared to balloon angioplasty were 1.72 (95% CI 1.13 to 2.63), 1.20 (95% CI 0.81 to 1.76) and 1.12 (95% CI 0.74 to 1.68). The corresponding odds ratios in trials not reporting concealment of treatment allocation were 0.60 (95% CI 0.28 to 1.28), 0.81 (95% CI 0.38 to 1.74), and 0.62 (95% CI 0.23 to 1.68) (tests for heterogeneity p &gt; 0.1 for all comparisons with the exception of 12 months mortality in trials with concealed treatment allocation where p = 0.09). </P>
<P>
<B>
<I>Blinded outcome assessment</I>
</B>
<BR/>Odds ratios for 30-days, 6 and 12 months mortality after primary stenting compared to balloon angioplasty were 1.45 (95% CI 0.91 to 2.30), 1.15 (0.78 to 1.68), and 1.07 (95% CI 0.71 to 1.60) in trials reporting blinded outcome assessment. The corresponding odds ratios in trials not reporting blinded outcome assessment were 1.17 (95% CI 0.63 to 2.18), 0.95 (95% CI 0.43 to 2.11), and 0.79 (95% CI 0.27 to 2.30) (tests for heterogeneity p &gt; 0.1 for all comparisons with the exception of 12 months mortality in trials with concealed treatment allocation where p = 0.08). </P>
<P>
<B>
<I>Excluding unpublished data</I>
</B>
<U>
<BR/>
</U>Odds ratios for 30-days and 6 months mortality for primary stenting compared to balloon angioplasty after exclusion of the two unpublished trials were 1.27 (95% CI 0.83 to 1.93) and 1.12 (95% CI 0.78 to 1.81) (tests of heterogeneity p &gt; 0.1). Odds ratios for 30-days, 6 and 12 months reinfarctions for primary stenting compared to balloon angioplasty after exclusion of the two unpublished trials were 0.55 (95% CI 0.31 to 0.99), 0.71 (95% CI 0.47 to 1.09) and 0.67 (95% CI 0.45 to 0.99) (tests of heterogeneity p &gt; 0.1). </P>
<P>
<B>Heterogeneity<BR/>
</B>There was no evidence of heterogeneity (p &gt; 0.1) for all but one summary estimate (reinfarction at 12 months, p=0.08). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Our meta-analysis found no evidence that primary stenting in acute myocardial infarction reduces overall mortality compared to balloon angioplasty. Contrary to the effect on mortality, primary stenting compared to balloon angioplasty reduces the risk of reinfarction and target vessel revascularization. At one year, on average 12 (95% CI 1 to 23) reinfarctions and 144 (95% CI 66 - 223) target vessel revascularizations are avoided per 1000 patients with acute myocardial infarction that are treated with primary stenting rather than balloon angioplasty. </P>
<P>This meta-analysis is based on a comprehensive literature search and the inclusion of additional unpublished data from individual trials. Although formal testing indicated no presence of publication bias, we cannot completely rule out such a bias. We explored heterogeneity between trials according to a priori defined criteria but lack of data precluded the detailed sensitivity analysis we envisaged. For the remaining criteria we found no evidence for heterogeneity. The test for heterogeneity has low power (<LINK REF="REF-Hardy-1998" TYPE="REFERENCE">Hardy 1998</LINK>), particularly in meta-analyses of rare events (<LINK REF="REF-Sutton-2002" TYPE="REFERENCE">Sutton 2002</LINK>), and this may be the main reason for our failure to detect heterogeneity. </P>
<P>This meta-analysis has some limitations. We were not able to obtain individual patient level data and had to rely on published and unpublished summary reports. The quality of included trials varied substantially. Only four trials reported concealed treatment allocation and only three reported blinded outcome assessment. Summary estimates in trials without reported concealed treatment allocation and without blinded outcome assessment indicated benefit from primary stenting, whereas both summary estimates in trials with higher quality indicated harm from routine stenting. Although our sensitivity analysis was inconclusive as 95% confidence intervals overlapped, this might be an indication that trial quality may have affected our summary estimates. By including trials of poorer quality into our analysis, we thus may underestimate the harmful effect of routine stenting on mortality in patients with acute myocardial infarction. </P>
<P>Cross-over rates from balloon angioplasty to stenting in some trials were substantial and ranged from 0 (<LINK REF="STD-PRISAM" TYPE="STUDY">PRISAM</LINK>) to 36% (<LINK REF="STD-STENTIM_x002d_2" TYPE="STUDY">STENTIM-2</LINK>) <I>(Characteristics of included studies table)</I>. Sensitivity analysis comparing trials with lower (&lt;15%) and higher ( &gt; 15%) crossover rates failed to reveal any difference in mortality. It is therefore unlikely that the crossover rates from balloon angioplasty to stenting in individual trials threaten the validity of our findings.</P>
<P>All trials used more aggressive post-interventional antithrombotic / anticoagulant therapies in patients assigned to stenting. The addition of an adenosine diphosphate (ADP) P2Y12 receptor antagonist (ticlopidine or clopidogrel) to aspirin following stenting has repeatedly been shown to offer greater protection from thrombotic complications than aspirin alone (<LINK REF="REF-Bertrand-1998" TYPE="REFERENCE">Bertrand 1998</LINK>; <LINK REF="REF-Leon-1998" TYPE="REFERENCE">Leon 1998</LINK>; <LINK REF="REF-Mehta-2001" TYPE="REFERENCE">Mehta 2001</LINK>; <LINK REF="REF-Steinhubl-2002" TYPE="REFERENCE">Steinhubl 2002</LINK>; <LINK REF="REF-Urban-1998" TYPE="REFERENCE">Urban 1998</LINK>). Thus, unbalanced cointervention might have introduced bias in favour of stenting and may explain the reduced odds of reinfarction and target vessel revascularization in this group. However, it is not clear whether the addition of antithrombotic or anticoagulant drugs to aspirin is similarly beneficial in patients treated with balloon angioplasty without stent placement. In the TOSCA trial ticlopidine added to aspirin did not improve clinical outcomes in patients treated with balloon angioplasty (<LINK REF="REF-Berger-2001" TYPE="REFERENCE">Berger 2001</LINK>), but coumarins added to aspirin prevented acute and late complications after angioplasty in another trial (<LINK REF="REF-ten-Berg-2000" TYPE="REFERENCE">ten Berg 2000</LINK>). Hence, further studies are needed to identify which antithrombotic strategy is most likely to be beneficial in stent recipients. </P>
<P>The external validity of our findings may be limited. Many trials were conducted in specialized high volume centres and some of them included highly pre-selected patients. Therefore, results from this analysis may not necessarily apply to patients treated in other centres or settings. Women and elderly patients were underrepresented in the included trials, and thus the results of our meta-analysis can not easily be generalized to these groups. </P>
<P>Contrary to a previous meta-analysis we found a significant reduction in reinfarction rates in patients treated with primary stenting (<LINK REF="REF-Zhu-2001" TYPE="REFERENCE">Zhu 2001</LINK>). This discrepant finding is mainly due to a difference in the inclusion of eligible trials. The previous systematic review included a large trial where there was no difference in reinfarction rate in the two treatment strategies (<LINK REF="REF-Antoniucci-1998" TYPE="REFERENCE">Antoniucci 1998</LINK>). This trial did not meet our inclusion criteria because it did not compare primary stenting to balloon angioplasty per se, but to optimal balloon angioplasty. In addition, our analysis included data from a relatively large unpublished trial (<LINK REF="STD-Jaksch" TYPE="STUDY">Jaksch</LINK>) where the reinfarction rate was lower in patients treated with stents. </P>
<P>Stent technology has developed considerably over the last few years. There is now a broad variety of stents with different physical and antithrombotic properties. Future trials comparing sirolimus-eluting stents to balloon angioplasty may show similar benefits of primary stenting in acute myocardial infarction as in chronic coronary artery disease (<LINK REF="REF-Morice-2002" TYPE="REFERENCE">Morice 2002</LINK>). However, so far these benefits have been limited to a reduction in restenosis and a reduced need for target vessel revascularizations, but not to a reduction of other end points like myocardial infarction or mortality. New stent types are more expensive and therefore, cost-effectiveness analyses and additional data on the long-term reliability will be important in justifying their use. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no evidence to suggest that primary stenting reduces mortality when compared to balloon angioplasty. Stenting seems to be associated with a reduced risk of reinfarction and target vessel revascularization, but potential confounding due to unbalanced post-interventional antithrombotic/anticoagulant therapies can not be ruled out on basis of this review.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Additional trials based on the use of modern sirolimus-eluting stents with extended follow-up periods and balanced antithrombotic therapies in both stent and balloon angioplasty arms are needed to better define the role of stents in the management of acute myocardial infarction.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank CL Grines, R Jaksch, B Scheller and GW Stone for providing us with additional data from their trials.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>AJ Nordmann analysed the data and wrote the manuscript. P Hengstler and T Harr collected the data. J Young gave statistical advice and helped writing the manuscript. HC Bucher designed the study and helped writing the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2012-11-26 15:58:13 +0000" MODIFIED_BY="[Empty name]">
<P>This review is no longer being updated as balloon angioplasty is the treatment comparison is no longer valid. Stents are now the standard intervention.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-GRAMI" NAME="GRAMI" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez A, Bernardi V, Fernandez M et al</AU>
<TI>In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction</TI>
<SO>The American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>11</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Grines" NAME="Grines" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Grines CL, Cox DA, Stone GW et al. 1999. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. New England Journal of Medicine. 1999;341;26; 1949-56.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grines CL, Cox DA, Stone GW et al</AU>
<TI>Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>26</NO>
<PG>1949-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jaksch" NAME="Jaksch" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Jaksch R, Niehus R, Knobloch W, Schiele T. PTCA versus stenting in acute myocardial infarction. European Heart Journal. 1998;19;239;1341.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jaksch R, Niehus R, Knobloch W, Schiele T</AU>
<TI>PTCA versus stenting in acute myocardial infarction</TI>
<SO>European Heart Journal</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>239</NO>
<PG>1341</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PASTA" NAME="PASTA" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saito S, Hosokawa G, Tanaka S, Nakamura S</AU>
<TI>Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>3</NO>
<PG>262-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-PRISAM" NAME="PRISAM" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kawashima A, Ueda K, Nishida Y, Inoue N, Tanaka S, Kato O et al</AU>
<TI>Quantitative angiographic analysis of restenosis of primary stenting using wiktor stent for acute myocardial infarction: results form a multicenter randomized PRISAM study</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>suppl 1</NO>
<PG>1-856</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Scheller" NAME="Scheller" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scheller B, Hennen B, Severin-Kneib S et al</AU>
<TI>Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction</TI>
<SO>The American Journal of Medicine</SO>
<YR>2001</YR>
<VL>110</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STENTIM_x002d_2" NAME="STENTIM-2" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maillard L, Hamon M, Khalife K et al</AU>
<TI>A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>7</NO>
<PG>1729-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Stone" NAME="Stone" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stone GW, Grines CL, Cox DA et al</AU>
<TI>Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>13</NO>
<PG>957-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suryapranata" NAME="Suryapranata" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suryapranata H, Ottervanger JP, Nibbering E et al</AU>
<TI>Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction</TI>
<SO>Heart</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>6</NO>
<PG>667-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Suryapranata H, van't Hof AW, Hoorntje JC et al</AU>
<TI>Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>25</NO>
<PG>2502-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE" NAME="ADVANCE" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Serruys PW, Foley DP, Suttorp MJ et al</AU>
<TI>A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>3</NO>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BENESTENT" NAME="BENESTENT" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiemeneij F, Serruys PW, Macaya C et al</AU>
<TI>Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1598-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macaya C, Serruys PW, Ruygrok P et al</AU>
<TI>Continued benefit of coronary stenting versus balloon angioplasty: one- year clinical follow-up of Benestent trial. Benestent Study Group</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>2</NO>
<PG>255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Serruys PW, de Jaegere P, Kiemeneij F et al</AU>
<TI>A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>8</NO>
<PG>489-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serruys PW, van Hout B, Bonnier H et al</AU>
<TI>Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>673-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BET" NAME="BET" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrie D, Khalife K, Citron B et al</AU>
<TI>Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. BET (Benefit Evaluation of Direct Coronary Stenting) Study Group</TI>
<SO>The American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>6</NO>
<PG>693-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BOSS" NAME="BOSS" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dangas G, Ambrose JA, Rehmann D et al</AU>
<TI>Balloon optimization versus stent study (BOSS): provisional stenting and early recoil after balloon angioplasty</TI>
<SO>The American Journal of Cardiology</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>8</NO>
<PG>957-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brener" NAME="Brener" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brener SJ, Ellis SG, Apperson-Hansen C et al</AU>
<TI>Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years</TI>
<SO>The American Journal of Cardiology</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briguori" NAME="Briguori" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briguori C, Nishida T, Adamian M et al</AU>
<TI>Coronary stenting versus balloon angioplasty in small coronary artery with complex lesions</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>4</NO>
<PG>390-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cura" NAME="Cura" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cura FA, Bhatt DL, Lincoff AM et al</AU>
<TI>Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>1</NO>
<PG>28-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DESTINI" NAME="DESTINI" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Di Mario C, Moses JW, Anderson TJ et al</AU>
<TI>Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint Stenting International Investigation)</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>24</NO>
<PG>2938-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moussa I, Moses J, Di Mario C et al</AU>
<TI>Selecting who qualifies for optimal balloon angioplasty versus elective stenting in coronary artery disease (a subanalysis of the DESTINI trial)</TI>
<SO>The American Journal of Cardiology</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>3</NO>
<PG>323-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doucet" NAME="Doucet" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Doucet S, Schalij MJ, Vrolix MC et al</AU>
<TI>Stent placement to prevent restenosis after angioplasty in small coronary arteries</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>17</NO>
<PG>2029-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eeckhout" NAME="Eeckhout" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eeckhout E, Stauffer JC, Vogt P et al</AU>
<TI>Comparison of elective Wiktor stent placement with conventional balloon angioplasty for new-onset lesions of the right coronary artery</TI>
<SO>American Heart Journal</SO>
<YR>1996</YR>
<VL>132</VL>
<NO>2 Pt 1</NO>
<PG>263-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elezi" NAME="Elezi" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elezi S, Kastrati A, Hadamitzky M et al</AU>
<TI>Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>2</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EPISTENT" NAME="EPISTENT" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marso SP, Lincoff AM, Ellis SG et al</AU>
<TI>Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>25</NO>
<PG>2477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The EPISTENT Investigators</AU>
<TI>Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9122</NO>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischman" NAME="Fischman" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fischman DL, Leon MB, Baim DS et al</AU>
<TI>A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>8</NO>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FRESCO" NAME="FRESCO" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Antoniucci D, Santoro GM, Bolognese L et al</AU>
<TI>A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FROST" NAME="FROST" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lafont A, Dubois-Rande JL, Steg PG et al</AU>
<TI>The French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. F.R.O.S.T. Study Group</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>2</NO>
<PG>404-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GISSOC" NAME="GISSOC" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubartelli P, Niccoli L, Verna E et al</AU>
<TI>Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>1</NO>
<PG>90-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruberg" NAME="Gruberg" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruberg L, Hong MK, Mehran R et al</AU>
<TI>In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site</TI>
<SO>The American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>12</NO>
<PG>1381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hancock" NAME="Hancock" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hancock J, Thomas MR, Holmberg S et al</AU>
<TI>Randomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries</TI>
<SO>Heart</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISAR_x002d_SMART" NAME="ISAR-SMART" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hausleiter J, Kastrati A, Mehilli J et al</AU>
<TI>Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial)</TI>
<SO>The American Journal of Cardiology</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>1</NO>
<PG>58-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kastrati A, Schomig A, Dirschinger J et al</AU>
<TI>A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR- SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>21</NO>
<PG>2593-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kastrati" NAME="Kastrati" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kastrati A, Dirschinger J, Boekstegers P et al</AU>
<TI>Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>3</NO>
<PG>290-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz" NAME="Katz" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz S, Green SJ, Kaplan BM et al</AU>
<TI>Nonrandomized comparison between stent deployment and percutaneous transluminal coronary angioplasty in acute myocardial infarction</TI>
<SO>American Heart Journal</SO>
<YR>2000</YR>
<VL>139</VL>
<NO>1 Pt 1</NO>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koning" NAME="Koning" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koning R, Eltchaninoff H, Commeau P et al</AU>
<TI>Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>14</NO>
<PG>1604-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kovar" NAME="Kovar" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kovar LI, Monrad ES, Sherman W et al</AU>
<TI>A randomized trial of stenting with or without balloon predilation for the treatment of coronary artery disease</TI>
<SO>American Heart Journal</SO>
<YR>2001</YR>
<VL>142</VL>
<NO>5</NO>
<PG>E9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lincoff" NAME="Lincoff" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lincoff AM, Califf RM, Moliterno DJ et al</AU>
<TI>Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators</TI>
<SO>New England Journal Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>5</NO>
<PG>319-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehilli" NAME="Mehilli" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehilli J, Kastrati A, Dirschinger J et al</AU>
<TI>A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>4</NO>
<PG>414-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miketic_x0028_a_x0029_" NAME="Miketic(a)" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miketic S, Carlsson J, Tebbe U</AU>
<TI>Randomized comparison of J&amp;J Crown stent versus NIR stent after routine coronary angioplasty</TI>
<SO>American Heart Journal</SO>
<YR>2001</YR>
<VL>142</VL>
<NO>5</NO>
<PG>E8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miketic_x0028_b_x0029_" NAME="Miketic(b)" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miketic S, Carlsson J, Tebbe U</AU>
<TI>Clinical and angiographic outcome after conventional angioplasty with optional stent implantation compared with direct stenting without predilatation</TI>
<SO>Heart</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>6</NO>
<PG>622-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori" NAME="Mori" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mori M, Kurogane H, Hayashi T et al</AU>
<TI>Comparison of results of intracoronary implantation of the Plamaz-Schatz stent with conventional balloon angioplasty in chronic total coronary arterial occlusion</TI>
<SO>The American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>9</NO>
<PG>985-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niazi" NAME="Niazi" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niazi K, Kinsara AJ, Amoudi O, Patel A, Buraiki J, Bakshi M et al</AU>
<TI>Stents in small coronary vessels: A prospective, randomized study</TI>
<SO>Circulation Supplement</SO>
<YR>1999</YR>
<VL>I 100</VL>
<NO>18</NO>
<PG>I-510. 2-11-0099</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OCBAS" NAME="OCBAS" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez A, Ayala F, Bernardi V et al</AU>
<TI>Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>5</NO>
<PG>1351-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-OPUS_x002d_1" NAME="OPUS-1" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weaver WD, Reisman MA, Griffin JJ et al</AU>
<TI>Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9222</NO>
<PG>2199-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prieto" NAME="Prieto" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prieto AR, Przybysz A, Fischell TA</AU>
<TI>Long balloon angioplasty with focal stenting for the treatment of diffuse coronary artery disease</TI>
<SO>Catheterization and Cardiovascular Interventions</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>4</NO>
<PG>437-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SARECCO" NAME="SARECCO" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sievert H, Rohde S, Utech A et al</AU>
<TI>Stent or angioplasty after recanalization of chronic coronary occlusions? (The SARECCO Trial)</TI>
<SO>The American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>4</NO>
<PG>386-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sasao" NAME="Sasao" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sasao H, Endo A, Hasegawa T et al</AU>
<TI>Long-term follow-up after coronary stent implantation in patients with coronary artery disease</TI>
<SO>Angiology</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>2</NO>
<PG>149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savage" NAME="Savage" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savage MP, Douglas JS Jr, Fischman DL et al</AU>
<TI>Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>11</NO>
<PG>740-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SICCO" NAME="SICCO" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sirnes PA, Golf S, Myreng Y et al</AU>
<TI>Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>6</NO>
<PG>1444-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SISCA" NAME="SISCA" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moer R, Myreng Y, Molstad P et al</AU>
<TI>Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated be stent</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1598-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-START" NAME="START" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Betriu A, Masotti M, Serra A et al</AU>
<TI>Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>5</NO>
<PG>1498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STOP" NAME="STOP" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lotan C, Rozenman Y, Hendler A et al</AU>
<TI>Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology</TI>
<SO>European Heart Journal</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>23</NO>
<PG>1960-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STRESS-I" NAME="STRESS I" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>George CJ, Baim DS, Brinker JA et al</AU>
<TI>One-year follow-up of the Stent Restenosis (STRESS I) Study</TI>
<SO>The American Journal of Cardiology</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>7</NO>
<PG>860-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Topol" NAME="Topol" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topol EJ, Mark DB, Lincoff AM et al</AU>
<TI>Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9195</NO>
<PG>2019-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TOSCA" NAME="TOSCA" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buller CE, Dzavik V, Carere RG et al</AU>
<TI>Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA)</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>3</NO>
<PG>236-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Versaci" NAME="Versaci" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Versaci F, Gaspardone A, Tomai F et al</AU>
<TI>A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>12</NO>
<PG>817-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waksman" NAME="Waksman" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waksman R, Weintraub WS, Ghazzal Z et al</AU>
<TI>Short- and long-term outcome of narrowed saphenous vein bypass graft: a comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty</TI>
<SO>American Heart Journal</SO>
<YR>1997</YR>
<VL>134</VL>
<NO>2 Pt 1</NO>
<PG>274-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WIDEST" NAME="WIDEST" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fluck DS, Chenu P, Mills P et al</AU>
<TI>Is provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators' Group</TI>
<SO>Heart</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>5</NO>
<PG>522-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witkowski-2000" NAME="Witkowski 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witkowski A, Ruzyllo W, Gil R et al</AU>
<TI>A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators</TI>
<SO>American Heart Journal</SO>
<YR>2000</YR>
<VL>140</VL>
<NO>2</NO>
<PG>264-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong" NAME="Wong" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong SC, Baim DS, Schatz RA et al</AU>
<TI>Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>3</NO>
<PG>704-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-Antoniucci-1998" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Antoniucci 1998" TYPE="JOURNAL_ARTICLE">
<AU>Antoniucci D, Santoro GM, Bolognese L et al</AU>
<TI>A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1234-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-2001" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Berger 2001" TYPE="JOURNAL_ARTICLE">
<AU>Berger PB, Dzavik V, Penn IM et al</AU>
<TI>Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA)</TI>
<SO>American Heart Journal</SO>
<YR>2001</YR>
<VL>142</VL>
<NO>5</NO>
<PG>776-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertrand-1998" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bertrand 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bertrand ME, Legrand V, Boland J et al</AU>
<TI>Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>16</NO>
<PG>1597-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cicchetti-1990" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Cicchetti 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cicchetti DV, Feinstein AR</AU>
<TI>High agreement but low kappa: II. Resolving the paradoxes</TI>
<SO>Journal fo Clinical Epidemiology</SO>
<YR>1990</YR>
<VL>43</VL>
<NO>6</NO>
<PG>551-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Boer-1995" MODIFIED="2008-09-09 10:10:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="de Boer 1995" TYPE="JOURNAL_ARTICLE">
<AU>de Boer MJ, Van Hout BA, Liem AL et al</AU>
<TI>A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction</TI>
<SO>American Journal of Cardiology</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>11</NO>
<PG>830-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-1998" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Deeks 1998" TYPE="CONFERENCE_PROC">
<AU>Deeks, JJ, Bradburn, MJ, Localio, R, and Berlin, J</AU>
<TI>Much ado about nothing: meta-analysis for rare events</TI>
<SO>6th Cochrane Colloquium Baltimore,MD,USA</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardy-1998" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Hardy 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hardy RJ, Thompson SG</AU>
<TI>Detecting and describing heterogeneity in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>8</NO>
<PG>841-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinincal Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keeley-2003" MODIFIED="2008-09-09 10:10:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Keeley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Keeley EC, Boura JA, Grines CL</AU>
<TI>Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials</TI>
<SO>The Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9351</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leon-1998" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Leon 1998" TYPE="JOURNAL_ARTICLE">
<AU>Leon MB, Baim DS, Popma JJ et al</AU>
<TI>A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>23</NO>
<PG>1665-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mehta-2001" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Mehta 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mehta SR, Yusuf S, Peters RJ et al</AU>
<TI>Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study</TI>
<SO>The Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>527-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morice-2002" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Morice 2002" TYPE="JOURNAL_ARTICLE">
<AU>Morice MC, Serruys PW, Sousa JE et al</AU>
<TI>A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>23</NO>
<PG>1773-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nunn-1999" MODIFIED="2008-09-09 10:10:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Nunn 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nunn CM, O'Neill WW, Rothbaum D et al</AU>
<TI>Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>3</NO>
<PG>640-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2000" NAME="Park 2000" TYPE="JOURNAL_ARTICLE">
<AU>Park SW, Lee CW, Hong MK et al</AU>
<TI>Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries</TI>
<SO>European Heart Journal</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>21</NO>
<PG>1785-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-Analyses" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="RevMan Analyses" NOTES="&lt;p&gt;RevMan Analyses [Computer program]. Version 1.0 for Windows. In: Review Manager (RevMan) 4.2. Oxford, England: The Cochrane Collaboration, 2003.&lt;/p&gt;" NOTES_MODIFIED="2008-09-09 10:10:06 +0100" NOTES_MODIFIED_BY="Karen Hovhannisyan" TYPE="OTHER">
<TI>RevMan Analyses [Computer program].</TI>
<SO>Version 1.0 for Windows. In: Review Manager (RevMan) 4.2. Oxford, England: The Cochrane Collaboration, 2003.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinhubl-2002" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Steinhubl 2002" TYPE="JOURNAL_ARTICLE">
<AU>Steinhubl SR, Berger PB, Mann JT, III et al</AU>
<TI>Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>19</NO>
<PG>2411-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stone-1995" MODIFIED="2008-09-09 10:10:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Stone 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stone GW, Grines CL, Browne KF et al</AU>
<TI>Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>1</NO>
<PG>66-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stone-1997" MODIFIED="2008-09-09 10:10:05 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Stone 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stone GW, Grines CL, Rothbaum D et al</AU>
<TI>Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>5</NO>
<PG>901-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutton-2002" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Sutton 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sutton AJ, Cooper NJ, Lambert PC, Jones DR, Abrams KP, Sweeting MJ</AU>
<TI>Meta-analysis of rare and adverse event data.</TI>
<SO>Pharmacoeconomics &amp; Outcomes Research</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>4</NO>
<PG>367</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ten-Berg-2000" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="ten Berg 2000" TYPE="JOURNAL_ARTICLE">
<AU>ten Berg JM, Kelder JC, Suttorp MJ et al</AU>
<TI>Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial</TI>
<SO>Circulation</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>4</NO>
<PG>386-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Urban-1998" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Urban 1998" TYPE="JOURNAL_ARTICLE">
<AU>Urban P, Macaya C, Rupprecht HJ et al</AU>
<TI>Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>20</NO>
<PG>2126-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhu-2001" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Zhu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Zhu MM, Feit A, Chadow H et al</AU>
<TI>Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>88</VL>
<NO>3</NO>
<PG>297-301</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Nordmann-2004" NAME="Nordmann 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nordmann AJ, Hengstler P, Harr T, Young J, Bucher HC</AU>
<TI>Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>116</VL>
<NO>4</NO>
<PG>253-62</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-GRAMI">
<CHAR_METHODS>
<P>RCT</P>
<P>Mean follow-up 12 months.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=52 <BR/>Angioplasty n=52<BR/>Mean Age 59 (10) 84% Male<BR/>Criteria for the need of target vessel revascularization:<BR/>Not specified.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type: <BR/>Gianturco<BR/>Roubin</P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: Ticlopidine 500 mg/d for 4 weeks in stent-group only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day and 12 month revascularisation. 30 Day myocardial infarction and mortality. Numbers of successful dilation and numbers with post interventional bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grines">
<CHAR_METHODS>
<P>RCTMean follow-up: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=452<BR/>Angioplasty n=433<BR/>Mean Age (SD) 60 (12)<BR/>75% Male<BR/>Criteria for the need of target vessel revascularization:<BR/>Clinical symptoms suggestive of ischemia and/or electrocardiographic changes during exercise testing.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type: <BR/>Heparin-coated Palmaz- Schatz </P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: Ticlopidine in 93% of stent- and 88% of PTCA-group<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day and 6 month revascularisation, myocardial infarction and 30 day, 6 month and 12 month mortality. Numbers of successful dilation and numbers with post interventional bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jaksch">
<CHAR_METHODS>
<P>RCTMean follow up: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=231<BR/>Angioplasty n=231<BR/>Mean Age (SD) 58 (12) <BR/>72% Male<BR/>Criteria for the need of target vessel revascularization: Not specified. </P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type:<BR/>Various types</P>
<P>Differences in Post-interventional / Anti-thrombotic/ Anti-coagulant therapy: Ticlopidine for 4 weeks in stent group only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day and 6 month revascularisation, myocardial infarction and mortality. Numbers of successful dilations.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 1<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PASTA">
<CHAR_METHODS>
<P>RCTMean follow-up 12 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=67<BR/>Angioplasty n=70<BR/>Mean Age (SD) 67 (11)<BR/>72 % Male<BR/>Criteria for the need of target vessel revascularization: Not specified. </P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 10</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type:<BR/>Palmaz-Schatz.</P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: Ticlopidine 200 mg for 4 weeks in stent-group only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day, 6 and 12 month revascularisation, myocardial infarction and mortality. Numbers of successful dilation and numbers with post interventional bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PRISAM">
<CHAR_METHODS>
<P>RCT Mean follow-up: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=110<BR/>Angioplasty n=112<BR/>Mean Age ( SD): Data not available<BR/>% Male: Data not available<BR/>Criteria for the need of target vessel revascularization: Not specified.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type<BR/>Wiktor </P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: No data<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 Day revascularisation and mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 1</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Scheller">
<CHAR_METHODS>
<P>RCTMean follow-up 24 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=44<BR/>Angioplasty n=44<BR/>Mean Age (SD) 61 (10)<BR/>76 % Male<BR/>Criteria for the need of target vessel revascularization: Not specified.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type: <BR/>Tensum III</P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: Ticlopidine 500 mg/d for 4 weeks in stent-group only, abciximab in 48% of patients in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day and 12 month revascularisation, myocardial infarction and mortality. Numbers of successful dilation and numbers with post interventional bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-STENTIM_x002d_2">
<CHAR_METHODS>
<P>RCTMean follow-up: 12 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=101<BR/>Angioplasty n=110<BR/>Mean Age (SD) 57 (12)<BR/>82 % Male<BR/>Criteria for the need of target vessel revascularization: Not specified.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 36</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type:<BR/>Wiktor<BR/>GX </P>
<P>Differences in Post-interventional Anti-thrombotic/Anti-coagulant therapy: Ticlopidine 500 mg/d for 4 weeks in stent-group only<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day, 6 and 12 month revascularisation, myocardial infarction and mortality. Numbers of successful dilation and numbers with post interventional bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stone">
<CHAR_METHODS>
<P>RCTMean follow-up 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=1036<BR/>Angioplasty n=1046<BR/>Mean Age 60 <BR/>73 % Male<BR/>Criteria for the need of target vessel revascularization:<BR/>Evidence of ischemia during functional testing or angina.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 16</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type: Multi-<BR/>Link and Multi Link Duet</P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: Ticlopidine 250 mg bid or clopidogrel 75 mg/d for 4 weeks in stent-group only<BR/>Abciximab for 50% of patients in both groups, approximately 50% of patients ticlopidine or clopidogrel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day, 6 and 12 month revascularisation, myocardial infarction and mortality. Numbers of successful dilation and numbers with post interventional bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Suryapranata">
<CHAR_METHODS>
<P>RCTMean follow-up 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Stent n=112<BR/>Angioplasty n=115<BR/>Mean Age (SD) 58 (11)<BR/>84% Male<BR/>Criteria for the need of target vessel revascularization:<BR/>Electrocardiographic or scintigraphic evidence of ischemia at rest or on exercise testing.</P>
<P>Cross over from Balloon angioplasty to Stenting (%) = 13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stent type:<BR/>Palmaz-Schatz</P>
<P>Differences in Post-interventional / Anti-thrombotic / Anti-coagulant therapy: Warfarin 3 months and ticlopidine 250 mg/d for 2 weeks in stent-group only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>30 day, 6 and 12 month revascularisation, myocardial infarction and mortality. Numbers of successful dilation and numbers with post interventional bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad score 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-ADVANCE">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-BENESTENT">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-BET">
<CHAR_REASON_FOR_EXCLUSION>
<P>Other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-BOSS">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brener">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not done on native coronary vessels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Briguori">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cura">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subgroup analysis of included trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DESTINI">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction (Di Mario 2000) AND Subgroup analysis of included trials (Moussa 2002)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doucet">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eeckhout">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elezi">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-EPISTENT">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subgroup analysis of included trials (Marso 1999). Intervention not within 24 hours after onset of symptoms of acute myocardial infarction (The Epistent investigators 1998)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fischman">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-FRESCO">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting, participants randomised after balloon angioplasty.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-FROST">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-GISSOC">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gruberg">
<CHAR_REASON_FOR_EXCLUSION>
<P>No native vessels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hancock">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ISAR_x002d_SMART">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subgroup analysis of included trials AND Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kastrati">
<CHAR_REASON_FOR_EXCLUSION>
<P>Stent versus stent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Katz">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koning">
<CHAR_REASON_FOR_EXCLUSION>
<P>No useful outcome data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kovar">
<CHAR_REASON_FOR_EXCLUSION>
<P>Other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lincoff">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mehilli">
<CHAR_REASON_FOR_EXCLUSION>
<P>Stent versus stent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miketic_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Stent versus stent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miketic_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mori">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niazi">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-OCBAS">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-OPUS_x002d_1">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prieto">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SARECCO">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sasao">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Savage">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not done on native coronary vessels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SICCO">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SISCA">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-START">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-STOP">
<CHAR_REASON_FOR_EXCLUSION>
<P>Provisional stenting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-STRESS-I">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Topol">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TOSCA">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Versaci">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waksman">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-WIDEST">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Witkowski-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not within 24 hours after onset of symptoms of acute myocardial infarction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wong">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention not done on native coronary vessels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-GRAMI">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Grines">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jaksch">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PASTA">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PRISAM">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-STENTIM_x002d_2">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Scheller">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stone">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Suryapranata">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Mortality</NAME>
<DICH_OUTCOME CHI2="7.937315022659803" CI_END="1.7311801722106595" CI_START="0.7796410869377925" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1617655491309224" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.23834226933404723" LOG_CI_START="-0.10810528171428008" LOG_EFFECT_SIZE="0.06511849380988363" METHOD="PETO" NO="1" P_CHI2="0.4396174871880394" P_Q="1.0" P_Z="0.46124881749735525" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2205" TOTAL_2="2223" WEIGHT="100.00000000000001" Z="0.736792061070524">
<NAME>30 Day</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.432301636068353" CI_START="0.1489333353961852" EFFECT_SIZE="0.6018727401612886" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.38601743193167454" LOG_CI_START="-0.8270080842607473" LOG_EFFECT_SIZE="-0.22049532616453643" ORDER="1" O_E="-1.0" SE="0.7125371927845743" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="1.9696312364425164" WEIGHT="8.157087457390167"/>
<DICH_DATA CI_END="2.55982746091579" CI_START="0.09620245495454854" EFFECT_SIZE="0.4962476055359538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4082106937112788" LOG_CI_START="-1.0168138452219584" LOG_EFFECT_SIZE="-0.3043015757553398" ORDER="2" O_E="-1.0" SE="0.8370664681546165" STUDY_ID="STD-GRAMI" TOTAL_1="52" TOTAL_2="52" VAR="1.4271844660194173" WEIGHT="5.910582799334495"/>
<DICH_DATA CI_END="4.009059130017349" CI_START="0.11656713156349036" EFFECT_SIZE="0.6836113830639046" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6030424617508636" LOG_CI_START="-0.9334238903395922" LOG_EFFECT_SIZE="-0.16519071429436424" ORDER="3" O_E="-0.46696035242290757" SE="0.9025279408490385" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="1.2276616466679044" WEIGHT="5.084273256165932"/>
<DICH_DATA CI_END="4.368343745045481" CI_START="0.8632996569337685" EFFECT_SIZE="1.9419551118567435" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.6403168056817079" LOG_CI_START="-0.06383843167288135" LOG_EFFECT_SIZE="0.28823918700441326" ORDER="4" O_E="3.879329608938548" SE="0.4136242720467261" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="5.845046470451345" WEIGHT="24.206843580576425"/>
<DICH_DATA CI_END="6.944459842300107" CI_START="0.002733342906575214" EFFECT_SIZE="0.13777369142890603" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8416384708610224" LOG_CI_START="-2.5633058812631986" LOG_EFFECT_SIZE="-0.8608337052010883" ORDER="5" O_E="-0.4954954954954955" SE="2.0000811671841405" STUDY_ID="STD-PRISAM" TOTAL_1="110" TOTAL_2="112" VAR="0.24997970943916895" WEIGHT="1.0352731591276196"/>
<DICH_DATA CI_END="1.9434551254053989" CI_START="0.0937562943356299" EFFECT_SIZE="0.4268619809324755" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28857451717525523" LOG_CI_START="-1.0279995662299053" LOG_EFFECT_SIZE="-0.3697125245273251" ORDER="6" O_E="-1.4233576642335768" SE="0.7733621337390114" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="1.671991989293986" WEIGHT="6.9244357179064515"/>
<DICH_DATA CI_END="408.54727881667617" CI_START="0.15971092390518615" EFFECT_SIZE="8.077713993374676" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.6112423221684806" LOG_CI_START="-0.796665377978656" LOG_EFFECT_SIZE="0.9072884720949124" ORDER="7" O_E="0.5213270142180095" SE="2.0018218524816103" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="0.24954515846454486" WEIGHT="1.0334734972218178"/>
<DICH_DATA CI_END="19.530847741512744" CI_START="0.20043019073720544" EFFECT_SIZE="1.9785276187333642" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2907210943616232" LOG_CI_START="-0.6980368602348324" LOG_EFFECT_SIZE="0.29634211706339536" ORDER="8" O_E="0.5" SE="1.1682062670406033" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="0.7327586206896551" WEIGHT="3.034667628910011"/>
<DICH_DATA CI_END="2.424092083719076" CI_START="0.7342814029180602" EFFECT_SIZE="1.3341535653873609" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="19" LOG_CI_END="0.3845491133042663" LOG_CI_START="-0.13413747099188963" LOG_EFFECT_SIZE="0.1252058211561883" ORDER="9" O_E="3.105667627281459" SE="0.304679067155563" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="10.77245690894332" WEIGHT="44.61336290336709"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2266057774911348" CI_END="1.8282186470490678" CI_START="0.8890498564123028" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2749029475412113" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2620281342470645" LOG_CI_START="-0.051073883846855746" LOG_EFFECT_SIZE="0.1054771252001044" METHOD="PETO" NO="2" P_CHI2="0.6650957102569786" P_Q="1.0" P_Z="0.18665586200611978" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1999" TOTAL_2="2015" WEIGHT="100.0" Z="1.3205367876167067">
<NAME>6 months</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.198633470652479" CI_START="0.7636347577708933" EFFECT_SIZE="1.562878016852108" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.5049644774104596" LOG_CI_START="-0.11711431238345092" LOG_EFFECT_SIZE="0.19392508251350435" ORDER="1" O_E="3.3441340782122904" SE="0.36541216046461544" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="7.489175500601264" WEIGHT="25.332668828969037"/>
<DICH_DATA CI_END="4.009059130017349" CI_START="0.11656713156349036" EFFECT_SIZE="0.6836113830639046" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6030424617508636" LOG_CI_START="-0.9334238903395922" LOG_EFFECT_SIZE="-0.16519071429436424" ORDER="2" O_E="-0.46696035242290757" SE="0.9025279408490385" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="1.2276616466679044" WEIGHT="4.152652842301263"/>
<DICH_DATA CI_END="2.2341285527032246" CI_START="0.22609179136448349" EFFECT_SIZE="0.710716628917048" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.34910815898701203" LOG_CI_START="-0.6457152051461218" LOG_EFFECT_SIZE="-0.14830352307955486" ORDER="3" O_E="-1.0" SE="0.5843641685468758" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="2.9284164859002173" WEIGHT="9.905577059136565"/>
<DICH_DATA CI_END="2.565517093893005" CI_START="0.14889099149987067" EFFECT_SIZE="0.6180472342949173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4091749126802261" LOG_CI_START="-0.8271315780050446" LOG_EFFECT_SIZE="-0.20897833266240923" ORDER="4" O_E="-0.9124087591240877" SE="0.726212552444356" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="1.8961491570894435" WEIGHT="6.4138593952056855"/>
<DICH_DATA CI_END="20.83609000444469" CI_START="0.21969644075787326" EFFECT_SIZE="2.139536121052224" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3188162247612956" LOG_CI_START="-0.6581769789089688" LOG_EFFECT_SIZE="0.33031962292616335" ORDER="5" O_E="0.5639810426540284" SE="1.1612955941101024" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="0.741505613723219" WEIGHT="2.5081954810330798"/>
<DICH_DATA CI_END="2.3898613524515753" CI_START="0.8767299390094399" EFFECT_SIZE="1.4475023308360808" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="26" LOG_CI_END="0.37837270613147367" LOG_CI_START="-0.05713416268874969" LOG_EFFECT_SIZE="0.16061927172136198" ORDER="6" O_E="5.65129682997118" SE="0.25581889053876805" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="15.280401925315187" WEIGHT="51.68704639335437"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.2630688984433505" CI_END="1.45423673063664" CI_START="0.7733853527997665" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0605118514084588" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="79" I2="20.166932839542593" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.16263510971463627" LOG_CI_START="-0.11160405731916481" LOG_EFFECT_SIZE="0.02551552619773578" METHOD="PETO" NO="3" P_CHI2="0.28145631438865826" P_Q="1.0" P_Z="0.7153244688042609" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1812" TOTAL_2="1828" WEIGHT="100.0" Z="0.36471458789098793">
<NAME>12 Months</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4397261796860485" CI_START="0.17064110170409594" EFFECT_SIZE="0.7661322763479218" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5365238718202127" LOG_CI_START="-0.7679163536295078" LOG_EFFECT_SIZE="-0.11569624090464756" ORDER="1" O_E="-0.4537444933920707" SE="0.7662346455124203" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="1.703242284566282" WEIGHT="4.419881203261192"/>
<DICH_DATA CI_END="3.45632458087207" CI_START="0.9729675948901558" EFFECT_SIZE="1.8338189154359883" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.5386145199939409" LOG_CI_START="-0.01190162385780214" LOG_EFFECT_SIZE="0.26335644806806946" ORDER="2" O_E="5.798882681564248" SE="0.3233759079973758" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="9.562791297810755" WEIGHT="24.815260806342817"/>
<DICH_DATA CI_END="1.983893791169754" CI_START="0.13408284312322974" EFFECT_SIZE="0.5157578113558374" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2975184182498277" LOG_CI_START="-0.8726267897367778" LOG_EFFECT_SIZE="-0.2875541857434751" ORDER="3" O_E="-1.4014598540145986" SE="0.6873490874835287" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="2.116631617216123" WEIGHT="5.4926186273869595"/>
<DICH_DATA CI_END="9.652613279897917" CI_START="0.279162234748377" EFFECT_SIZE="1.6415374179037663" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9846449070633383" LOG_CI_START="-0.5541433337198036" LOG_EFFECT_SIZE="0.2152507866717674" ORDER="4" O_E="0.6066350710900474" SE="0.903891829760657" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="1.2239595867546722" WEIGHT="3.1761517548431852"/>
<DICH_DATA CI_END="1.5644785338877782" CI_START="0.13891842998353898" EFFECT_SIZE="0.4661919150635702" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.19436960859563937" LOG_CI_START="-0.8572401336058659" LOG_EFFECT_SIZE="-0.3314352625051133" ORDER="5" O_E="-2.0" SE="0.6177207681213422" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="2.6206896551724137" WEIGHT="6.800639610369447"/>
<DICH_DATA CI_END="1.5085615067107732" CI_START="0.6453097402261773" EFFECT_SIZE="0.9866556815884352" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" LOG_CI_END="0.17856302182325995" LOG_CI_START="-0.19023177965568824" LOG_EFFECT_SIZE="-0.005834378916214141" ORDER="6" O_E="-0.2862632084534127" SE="0.2166318919524438" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="21.30861460810107" WEIGHT="55.295447997796394"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Myocardial Infarction</NAME>
<DICH_OUTCOME CHI2="8.305641250847" CI_END="0.8720237606296164" CI_START="0.30589092524284595" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5164728017744394" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" I2="15.719933132361719" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.059471681386536294" LOG_CI_START="-0.5144334068839578" LOG_EFFECT_SIZE="-0.286952544135247" METHOD="PETO" NO="1" P_CHI2="0.3064160325982036" P_Q="1.0" P_Z="0.013422086475622198" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2095" TOTAL_2="2111" WEIGHT="100.00000000000003" Z="2.4723690818708755">
<NAME>30 day</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.304325321878246" CI_START="0.11953068249692862" EFFECT_SIZE="0.3948504728655302" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.11538592565628845" LOG_CI_START="-0.9225206007516286" LOG_EFFECT_SIZE="-0.4035673375476701" ORDER="1" O_E="-2.5" SE="0.6096714313321763" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="2.690347071583514" WEIGHT="19.21468366881173"/>
<DICH_DATA CI_END="0.9315980772077749" CI_START="0.017437256301170795" EFFECT_SIZE="0.12745396989482075" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.03077141650802564" LOG_CI_START="-1.758521848933372" LOG_EFFECT_SIZE="-0.8946466327206988" ORDER="2" O_E="-2.0" SE="1.014889156509222" STUDY_ID="STD-GRAMI" TOTAL_1="52" TOTAL_2="52" VAR="0.9708737864077669" WEIGHT="6.934061736944053"/>
<DICH_DATA CI_END="1.3254393363480652" CI_START="0.0520708512607615" EFFECT_SIZE="0.26271040051384065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.12235985542468605" LOG_CI_START="-1.2834053223659934" LOG_EFFECT_SIZE="-0.5805227334706535" ORDER="3" O_E="-1.960352422907489" SE="0.8257534240841028" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="1.466557967100578" WEIGHT="10.474279589223052"/>
<DICH_DATA CI_END="1.8283141858304175" CI_START="0.093486621767044" EFFECT_SIZE="0.41342824862610594" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.262050828951285" LOG_CI_START="-1.029250533602904" LOG_EFFECT_SIZE="-0.38359985232580956" ORDER="4" O_E="-1.535195530726257" SE="0.7585168124091649" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="1.7380792604442004" WEIGHT="12.413507362490813"/>
<DICH_DATA CI_END="1.342040411860245" CI_START="0.014025207391898827" EFFECT_SIZE="0.13719473424533926" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.1277655936151345" LOG_CI_START="-1.853090708075985" LOG_EFFECT_SIZE="-0.8626625572304251" ORDER="5" O_E="-1.467153284671533" SE="1.1635647970101963" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="0.7386162414243763" WEIGHT="5.275258936484585"/>
<DICH_DATA CI_END="4.478511817266692" CI_START="0.26647637799907764" EFFECT_SIZE="1.0924365463912744" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6511337245071509" LOG_CI_START="-0.5743412832953558" LOG_EFFECT_SIZE="0.03839622060589751" ORDER="6" O_E="0.17061611374407581" SE="0.7198500857823155" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="1.9298158921258135" WEIGHT="13.782906413044241"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="7" O_E="-0.5" SE="2.0" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="0.25" WEIGHT="1.7855208972630938"/>
<DICH_DATA CI_END="2.9524974745760115" CI_START="0.4377238176817084" EFFECT_SIZE="1.1368282483590098" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.47018953481115044" LOG_CI_START="-0.3587998216612433" LOG_EFFECT_SIZE="0.055694856574953544" ORDER="8" O_E="0.540826128722383" SE="0.48695245155538003" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="4.21722611058586" WEIGHT="30.119781395738446"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.240979293997713" CI_END="0.9955828569318094" CI_START="0.44646242809208697" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6667010871992278" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="59" I2="39.32759904345674" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.0019225901711353492" LOG_CI_START="-0.35021508315583666" LOG_EFFECT_SIZE="-0.17606883666348605" METHOD="PETO" NO="2" P_CHI2="0.1434455111561671" P_Q="1.0" P_Z="0.04752378495246128" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1999" TOTAL_2="2015" WEIGHT="99.99999999999999" Z="1.9816021626136857">
<NAME>6 Month</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.304325321878246" CI_START="0.11953068249692862" EFFECT_SIZE="0.3948504728655302" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.11538592565628845" LOG_CI_START="-0.9225206007516286" LOG_EFFECT_SIZE="-0.4035673375476701" ORDER="1" O_E="-2.5" SE="0.6096714313321763" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="2.690347071583514" WEIGHT="11.26086474342934"/>
<DICH_DATA CI_END="0.7749184677504769" CI_START="0.054148048863945995" EFFECT_SIZE="0.20484219061835618" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.11074398893725203" LOG_CI_START="-1.2664171878454618" LOG_EFFECT_SIZE="-0.6885805883913569" ORDER="2" O_E="-3.4405286343612334" SE="0.6788481577132789" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="2.1699749105967823" WEIGHT="9.082766392100798"/>
<DICH_DATA CI_END="2.5651763725550345" CI_START="0.45460758153579606" EFFECT_SIZE="1.0798836173125372" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.409117231043959" LOG_CI_START="-0.3423633257784374" LOG_EFFECT_SIZE="0.033376952632760776" ORDER="3" O_E="0.39441340782122936" SE="0.4414233989662255" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="5.132031329825105" WEIGHT="21.480912732269513"/>
<DICH_DATA CI_END="0.9813088826822491" CI_START="0.01861644648376232" EFFECT_SIZE="0.13516095700495276" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.008194269959569175" LOG_CI_START="-1.7301032137829417" LOG_EFFECT_SIZE="-0.8691487418712555" ORDER="4" O_E="-1.9562043795620438" SE="1.0114578371885876" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="0.9774722398949457" WEIGHT="4.091361594262695"/>
<DICH_DATA CI_END="2.556938067566642" CI_START="0.20238686051066115" EFFECT_SIZE="0.7193682422897257" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.40772020896501554" LOG_CI_START="-0.6938176864614303" LOG_EFFECT_SIZE="-0.1430487387482073" ORDER="5" O_E="-0.7867298578199051" SE="0.6470488124740166" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="2.388503659589215" WEIGHT="9.997452348774107"/>
<DICH_DATA CI_END="1.6020876430849305" CI_START="0.47877535632742696" EFFECT_SIZE="0.8758082451003503" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.20468627071639434" LOG_CI_START="-0.31986821182964453" LOG_EFFECT_SIZE="-0.05759097055662509" ORDER="6" O_E="-1.3967339097022098" SE="0.308125899634109" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="10.532794009338739" WEIGHT="44.08664218916355"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.699276358796673" CI_END="0.9848536691424389" CI_START="0.4496435935674879" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.66545709323091" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="62" I2="48.44976248702004" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.006628292756154145" LOG_CI_START="-0.34713158994786225" LOG_EFFECT_SIZE="-0.1768799413520082" METHOD="PETO" NO="3" P_CHI2="0.08421868404216781" P_Q="1.0" P_Z="0.04172325636107971" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1812" TOTAL_2="1828" WEIGHT="100.0" Z="2.036269942151593">
<NAME>12 Month</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6214484057351305" CI_START="0.05536444178104918" EFFECT_SIZE="0.1854889324980023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.2065949217844491" LOG_CI_START="-1.2567690745553481" LOG_EFFECT_SIZE="-0.7316819981698987" ORDER="1" O_E="-4.427312775330397" SE="0.6168774957835219" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="2.627859524759406" WEIGHT="10.512838509830347"/>
<DICH_DATA CI_END="2.354462325288711" CI_START="0.48036011078423185" EFFECT_SIZE="1.0634800343273894" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.37189174551132725" LOG_CI_START="-0.3184330636870256" LOG_EFFECT_SIZE="0.026729340912150824" ORDER="2" O_E="0.3743016759776534" SE="0.40550021008602927" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="6.0815997288708745" WEIGHT="24.32963985656771"/>
<DICH_DATA CI_END="0.9813088826822491" CI_START="0.01861644648376232" EFFECT_SIZE="0.13516095700495276" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.008194269959569175" LOG_CI_START="-1.7301032137829417" LOG_EFFECT_SIZE="-0.8691487418712555" ORDER="3" O_E="-1.9562043795620438" SE="1.0114578371885876" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="0.9774722398949457" WEIGHT="3.9104098636317075"/>
<DICH_DATA CI_END="2.556938067566642" CI_START="0.20238686051066115" EFFECT_SIZE="0.7193682422897257" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.40772020896501554" LOG_CI_START="-0.6938176864614303" LOG_EFFECT_SIZE="-0.1430487387482073" ORDER="4" O_E="-0.7867298578199051" SE="0.6470488124740166" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="2.388503659589215" WEIGHT="9.555287494181849"/>
<DICH_DATA CI_END="1.7107960215915383" CI_START="0.04723493922075407" EFFECT_SIZE="0.2842698473264166" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.23319823164623554" LOG_CI_START="-1.3257366391329701" LOG_EFFECT_SIZE="-0.5462692037433673" ORDER="5" O_E="-1.5" SE="0.9157260599477717" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="1.1925287356321839" WEIGHT="4.770750452188318"/>
<DICH_DATA CI_END="1.5092391097189426" CI_START="0.4804690208430963" EFFECT_SIZE="0.8515530736629201" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.1787580507795882" LOG_CI_START="-0.3183346090581343" LOG_EFFECT_SIZE="-0.06978827913927307" ORDER="6" O_E="-1.8847262247838614" SE="0.29199468903702924" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="11.728705871776633" WEIGHT="46.921073823600075"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Revascularisation</NAME>
<DICH_OUTCOME CHI2="8.750287977803303" CI_END="0.5953839966998968" CI_START="0.3374032817940979" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4482014217003685" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="146" I2="8.574437546587555" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.2252028429145754" LOG_CI_START="-0.4718506975081979" LOG_EFFECT_SIZE="-0.34852677021138667" METHOD="PETO" NO="1" P_CHI2="0.3637976190921294" P_Q="1.0" P_Z="3.0408136985989814E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2205" TOTAL_2="2223" WEIGHT="100.0" Z="5.53907041590013">
<NAME>30 Day</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.808806193457655" CI_START="0.1230565401034116" EFFECT_SIZE="0.3154819991395858" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.09215553178131734" LOG_CI_START="-0.9098952998372968" LOG_EFFECT_SIZE="-0.501025415809307" ORDER="1" O_E="-5.0" SE="0.4803443876332175" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="4.334056399132321" WEIGHT="9.097549912217005"/>
<DICH_DATA CI_END="1.2787273199936988" CI_START="0.013232581133852972" EFFECT_SIZE="0.13008021759626248" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10677794397227086" LOG_CI_START="-1.8783554345083084" LOG_EFFECT_SIZE="-0.8857887452680188" ORDER="2" O_E="-1.5" SE="1.1660771730881967" STUDY_ID="STD-GRAMI" TOTAL_1="52" TOTAL_2="52" VAR="0.7354368932038834" WEIGHT="1.5437440649243999"/>
<DICH_DATA CI_END="0.5331222951193246" CI_START="0.03190451080853334" EFFECT_SIZE="0.13041858006781315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.2731731549448736" LOG_CI_START="-1.496147910022418" LOG_EFFECT_SIZE="-0.884660532483646" ORDER="3" O_E="-3.947136563876652" SE="0.7183814249552221" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="1.9377145990650169" WEIGHT="4.067426368552743"/>
<DICH_DATA CI_END="0.8405282565627937" CI_START="0.16057013985509203" EFFECT_SIZE="0.36737411409684884" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.07544768203054902" LOG_CI_START="-0.7943352143617107" LOG_EFFECT_SIZE="-0.4348914481961298" ORDER="4" O_E="-5.6156424581005595" SE="0.4222780950420009" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="5.607933984470541" WEIGHT="11.771526401537514"/>
<DICH_DATA CI_END="1.034214979514233" CI_START="0.32274473179482654" EFFECT_SIZE="0.5777433999463024" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="38" LOG_CI_END="0.014610823779562817" LOG_CI_START="-0.4911408380502626" LOG_EFFECT_SIZE="-0.2382650071353499" ORDER="5" O_E="-6.216216216216218" SE="0.2970810296699416" STUDY_ID="STD-PRISAM" TOTAL_1="110" TOTAL_2="112" VAR="11.330528278064051" WEIGHT="23.783734462272008"/>
<DICH_DATA CI_END="1.4089386434038185" CI_START="0.14444200633876075" EFFECT_SIZE="0.45112074266371227" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.14889208082308888" LOG_CI_START="-0.8403064877348191" LOG_EFFECT_SIZE="-0.34570720345586514" ORDER="6" O_E="-2.3576642335766422" SE="0.581060135782801" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="2.9618143810350612" WEIGHT="6.217098182567036"/>
<DICH_DATA CI_END="3.036400632167996" CI_START="0.26881994335398657" EFFECT_SIZE="0.9034628082768043" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4823590731723172" LOG_CI_START="-0.57053851475774" LOG_EFFECT_SIZE="-0.04408972079271145" ORDER="7" O_E="-0.2654028436018958" SE="0.6184772550772327" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="2.614282612485708" WEIGHT="5.487599689863582"/>
<DICH_DATA CI_END="0.9261007346334115" CI_START="0.0171443796324528" EFFECT_SIZE="0.12600564500231182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.03334177129213024" LOG_CI_START="-1.765878225164199" LOG_EFFECT_SIZE="-0.8996099982281646" ORDER="8" O_E="-2.0" SE="1.0177004891982149" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="0.9655172413793103" WEIGHT="2.0267021205152926"/>
<DICH_DATA CI_END="0.8292186937182822" CI_START="0.3218219742452685" EFFECT_SIZE="0.5165857112750025" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="47" LOG_CI_END="-0.08133091583145244" LOG_CI_START="-0.49238430527227495" LOG_EFFECT_SIZE="-0.2868576105518636" ORDER="9" O_E="-11.329490874159461" SE="0.24145479570463282" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="17.15253557315367" WEIGHT="36.004618797550414"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6478396461009117" CI_END="0.5133599091359456" CI_START="0.35007081278307045" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4239248997658237" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="333" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.28957805058643293" LOG_CI_START="-0.4558440971060484" LOG_EFFECT_SIZE="-0.3727110738462407" METHOD="PETO" NO="2" P_CHI2="0.7540838897273114" P_Q="1.0" P_Z="1.534357895797765E-18" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1999" TOTAL_2="2015" WEIGHT="100.0" Z="8.787125172807894">
<NAME>6 Month</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7835573284645955" CI_START="0.165774360440421" EFFECT_SIZE="0.36040770662490446" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.10592922315837103" LOG_CI_START="-0.7804826389263249" LOG_EFFECT_SIZE="-0.44320593104234796" ORDER="1" O_E="-6.5" SE="0.39623601551535637" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="6.3693058568329715" WEIGHT="6.07539401337575"/>
<DICH_DATA CI_END="0.5737301789323832" CI_START="0.10265722613139958" EFFECT_SIZE="0.24268817177001029" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.24129230507818766" LOG_CI_START="-0.9886104748512363" LOG_EFFECT_SIZE="-0.6149513899647119" ORDER="2" O_E="-7.348017621145374" SE="0.43897839220929036" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="5.189358960509736" WEIGHT="4.949895808209015"/>
<DICH_DATA CI_END="0.6262026460366465" CI_START="0.2828785990918268" EFFECT_SIZE="0.420879231203491" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="76" LOG_CI_END="-0.20328510159184932" LOG_CI_START="-0.5483999074312877" LOG_EFFECT_SIZE="-0.37584250451156853" ORDER="3" O_E="-21.05810055865922" SE="0.20272214529592686" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="24.333109646218805" WEIGHT="23.21025744318094"/>
<DICH_DATA CI_END="0.903064073788592" CI_START="0.19256909776921136" EFFECT_SIZE="0.4170158677044048" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="-0.044281434730108475" LOG_CI_START="-0.715413404361448" LOG_EFFECT_SIZE="-0.3798474195457782" ORDER="4" O_E="-5.627737226277372" SE="0.39422624111827753" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="6.434413128030263" WEIGHT="6.137496907246815"/>
<DICH_DATA CI_END="1.1009271607940487" CI_START="0.2984678658245639" EFFECT_SIZE="0.5732289072530242" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="29" LOG_CI_END="0.04175858626361716" LOG_CI_START="-0.5251024197986215" LOG_EFFECT_SIZE="-0.2416719167675022" ORDER="5" O_E="-5.018957345971565" SE="0.33297696096819374" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="9.019275013075692" WEIGHT="8.603080249419163"/>
<DICH_DATA CI_END="0.569840823812731" CI_START="0.33341797033047416" EFFECT_SIZE="0.4358843549464538" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="166" LOG_CI_END="-0.2442464408081864" LOG_CI_START="-0.47701099657447826" LOG_EFFECT_SIZE="-0.36062871869133234" ORDER="6" O_E="-44.41882804995197" SE="0.13672705226025336" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="53.49227866462532" WEIGHT="51.02387557856831"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0102135234571232" CI_END="0.5736945658190803" CI_START="0.3777346357363426" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4655150994796941" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="278" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.24131926384592658" LOG_CI_START="-0.4228131914512178" LOG_EFFECT_SIZE="-0.3320662276485722" METHOD="PETO" NO="3" P_CHI2="0.6984113189178935" P_Q="1.0" P_Z="7.390623920416425E-13" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1412" TOTAL_2="1437" WEIGHT="100.0" Z="7.1720068573170925">
<NAME>12 Month</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8526323222345258" CI_START="0.2340296875490714" EFFECT_SIZE="0.6584610569470731" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2677892367668781" LOG_CI_START="-0.6307290472012387" LOG_EFFECT_SIZE="-0.1814699052171803" ORDER="1" O_E="-1.5" SE="0.5277940877401096" STUDY_ID="STD-GRAMI" TOTAL_1="52" TOTAL_2="52" VAR="3.589805825242718" WEIGHT="4.080095797555187"/>
<DICH_DATA CI_END="0.8060631073940309" CI_START="0.1701477148262286" EFFECT_SIZE="0.3703374079522932" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.09363095556451208" LOG_CI_START="-0.7691738793335174" LOG_EFFECT_SIZE="-0.4314024174490148" ORDER="2" O_E="-6.308370044052863" SE="0.3968172574133177" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="6.3506605181685645" WEIGHT="7.218023635060335"/>
<DICH_DATA CI_END="0.9223577717038962" CI_START="0.202418580607539" EFFECT_SIZE="0.4320906744661764" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.03510058855788317" LOG_CI_START="-0.6937496248117171" LOG_EFFECT_SIZE="-0.3644251066848001" ORDER="3" O_E="-5.605839416058394" SE="0.38689370426081393" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="6.680618541838388" WEIGHT="7.593046801014955"/>
<DICH_DATA CI_END="1.048538327535355" CI_START="0.2871302907769959" EFFECT_SIZE="0.5486958309264355" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="30" LOG_CI_END="0.020584309987708015" LOG_CI_START="-0.5419209892402453" LOG_EFFECT_SIZE="-0.2606683396262687" ORDER="4" O_E="-5.497630331753555" SE="0.3304183972126379" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="9.159495625927198" WEIGHT="10.410484976173848"/>
<DICH_DATA CI_END="0.6197149255849025" CI_START="0.09094163483034265" EFFECT_SIZE="0.23739816440203398" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.2078080439163171" LOG_CI_START="-1.041237242879812" LOG_EFFECT_SIZE="-0.6245226433980646" ORDER="5" O_E="-6.0" SE="0.4895604370122276" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="4.172413793103448" WEIGHT="4.742275435399529"/>
<DICH_DATA CI_END="0.6233204457945084" CI_START="0.37259190082310234" EFFECT_SIZE="0.4819171606412034" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="176" LOG_CI_END="-0.2052886273995119" LOG_CI_START="-0.42876658976737736" LOG_EFFECT_SIZE="-0.3170276085834446" ORDER="6" O_E="-42.361191162343914" SE="0.13127206132863897" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="58.03037675758904" WEIGHT="65.95607335479615"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.921572891501594" CI_END="1.2882470176502714" CI_START="0.7098440888782178" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9562711595013406" ESTIMABLE="YES" EVENTS_1="2000" EVENTS_2="2018" I2="58.63268713326548" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.10999914572303708" LOG_CI_START="-0.14883702983785205" LOG_EFFECT_SIZE="-0.019418942057407473" METHOD="PETO" NO="4" P_CHI2="0.017908969037840894" P_Q="1.0" P_Z="0.7686899494781303" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2095" TOTAL_2="2111" WEIGHT="99.99999999999999" Z="0.29408893071390185">
<NAME>Successful dilation</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Balloon Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Stenting</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.894279848717293" CI_START="0.34550909112786277" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="224" LOG_CI_END="0.46154052086656655" LOG_CI_START="-0.4615405208665665" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.542222373238892" STUDY_ID="STD-Jaksch" TOTAL_1="231" TOTAL_2="231" VAR="3.401301518438178" WEIGHT="7.8626742912696495"/>
<DICH_DATA CI_END="20.834167417683652" CI_START="0.5829670534320416" EFFECT_SIZE="3.4850585633812363" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="48" LOG_CI_END="1.3187761497114376" LOG_CI_START="-0.23435598883786318" LOG_EFFECT_SIZE="0.5422100804367873" ORDER="2" O_E="1.5" SE="0.9123175063119376" STUDY_ID="STD-GRAMI" TOTAL_1="52" TOTAL_2="52" VAR="1.2014563106796114" WEIGHT="2.777366133185985"/>
<DICH_DATA CI_END="2.4831894722042205" CI_START="0.0975539099478482" EFFECT_SIZE="0.49218374836523726" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="113" LOG_CI_END="0.3950098583356227" LOG_CI_START="-1.0107553194550565" LOG_EFFECT_SIZE="-0.307872730559717" ORDER="3" O_E="-1.0396475770925093" SE="0.8257534240841028" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="1.4665579671005777" WEIGHT="3.390192713603724"/>
<DICH_DATA CI_END="1.3982629412470629" CI_START="0.1566084472134721" EFFECT_SIZE="0.46795276259986424" ESTIMABLE="YES" EVENTS_1="443" EVENTS_2="439" LOG_CI_END="0.14558884751480727" LOG_CI_START="-0.8051848164846019" LOG_EFFECT_SIZE="-0.32979798448489733" ORDER="4" O_E="-2.43463687150836" SE="0.5584891566387937" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="3.2060516087923423" WEIGHT="7.411321643871907"/>
<DICH_DATA CI_END="4.754696976841175" CI_START="0.04968971917425113" EFFECT_SIZE="0.4860653840152566" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="69" LOG_CI_END="0.6771228439907324" LOG_CI_START="-1.303733457700387" LOG_EFFECT_SIZE="-0.31330530685482716" ORDER="5" O_E="-0.5328467153284606" SE="1.1635647970101963" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="0.7386162414243763" WEIGHT="1.7074343162697228"/>
<DICH_DATA CI_END="2.716058264170016" CI_START="0.6159936321176585" EFFECT_SIZE="1.2934738478953762" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="91" LOG_CI_END="0.43393908207979076" LOG_CI_START="-0.21042377736553683" LOG_EFFECT_SIZE="0.11175765235712698" ORDER="6" O_E="1.7962085308056857" SE="0.37850193328578163" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="6.98013457533684" WEIGHT="16.135742267361383"/>
<DICH_DATA CI_END="0.531032690343347" CI_START="0.07559084383185699" EFFECT_SIZE="0.20035271189917747" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" LOG_CI_END="-0.27487874295105896" LOG_CI_START="-1.121530806537435" LOG_EFFECT_SIZE="-0.698204774744247" ORDER="7" O_E="-6.5" SE="0.4973276131459436" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="4.043103448275862" WEIGHT="9.346306220537471"/>
<DICH_DATA CI_END="1.9217435279472201" CI_START="0.8366739978530554" EFFECT_SIZE="1.2680192586770263" ESTIMABLE="YES" EVENTS_1="995" EVENTS_2="994" LOG_CI_END="0.28369542712569845" LOG_CI_START="-0.07744372780454627" LOG_EFFECT_SIZE="0.10312584966057603" ORDER="8" O_E="5.276657060518687" SE="0.21213492727367378" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="22.221616130404232" WEIGHT="51.36896241390016"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="2.6200317860218205" CI_END="1.8762013974311005" CI_START="0.9515651343918221" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.3361616050810057" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2732794550976299" LOG_CI_START="-0.02156147901249196" LOG_EFFECT_SIZE="0.12585898804256895" METHOD="PETO" NO="1" P_CHI2="0.8547997660667811" P_Q="1.0" P_Z="0.09426769700188081" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1864" TOTAL_2="1880" WEIGHT="100.00000000000003" Z="1.67330282301954">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>Stenting</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stenting</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.205680050072843" CI_START="0.061706759414610624" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096672603479972" LOG_CI_START="-1.2096672603479972" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="1.4211290733558495" STUDY_ID="STD-GRAMI" TOTAL_1="52" TOTAL_2="52" VAR="0.4951456310679611" WEIGHT="1.4851957997336165"/>
<DICH_DATA CI_END="8.381301699144027" CI_START="0.6674524364524999" EFFECT_SIZE="2.3651892608705034" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9233114741020093" LOG_CI_START="-0.17557967726257737" LOG_EFFECT_SIZE="0.37386589841971596" ORDER="2" O_E="2.066079295154185" SE="0.6454941019104862" STUDY_ID="STD-Suryapranata" TOTAL_1="112" TOTAL_2="115" VAR="2.4000232191615787" WEIGHT="7.198901051946643"/>
<DICH_DATA CI_END="16.892388197786225" CI_START="0.06466205533168613" EFFECT_SIZE="1.0451299155270481" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2276910532299747" LOG_CI_START="-1.189350495130845" LOG_EFFECT_SIZE="0.019170279049565007" ORDER="3" O_E="0.021897810218978075" SE="1.4197821700557716" STUDY_ID="STD-PASTA" TOTAL_1="67" TOTAL_2="70" VAR="0.49608553528502886" WEIGHT="1.48801505473205"/>
<DICH_DATA CI_END="2.525628217997365" CI_START="0.7109732767723995" EFFECT_SIZE="1.3400202125559235" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.40236942113791674" LOG_CI_START="-0.14814672271382645" LOG_EFFECT_SIZE="0.12711134921204512" ORDER="4" O_E="2.7988826815642476" SE="0.3233759079973758" STUDY_ID="STD-Grines" TOTAL_1="452" TOTAL_2="443" VAR="9.562791297810755" WEIGHT="28.68371763395068"/>
<DICH_DATA CI_END="4.264002379845402" CI_START="0.12331877376761836" EFFECT_SIZE="0.7251424307160226" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6298174384090969" LOG_CI_START="-0.9089708023740453" LOG_EFFECT_SIZE="-0.1395766819824741" ORDER="5" O_E="-0.39336492890995256" SE="0.903891829760657" STUDY_ID="STD-STENTIM_x002d_2" TOTAL_1="101" TOTAL_2="110" VAR="1.2239595867546722" WEIGHT="3.6712827968833026"/>
<DICH_DATA CI_END="2.3702588605692627" CI_START="0.17285419118890405" EFFECT_SIZE="0.6400852898263115" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.37479577874330755" LOG_CI_START="-0.7623200856723631" LOG_EFFECT_SIZE="-0.19376215346452774" ORDER="6" O_E="-1.0" SE="0.6679474875720741" STUDY_ID="STD-Scheller" TOTAL_1="44" TOTAL_2="44" VAR="2.2413793103448274" WEIGHT="6.723046571478406"/>
<DICH_DATA CI_END="2.318804438005901" CI_START="0.8941037984917403" EFFECT_SIZE="1.4398791115856153" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="29" LOG_CI_END="0.36526412290437016" LOG_CI_START="-0.04861206006826087" LOG_EFFECT_SIZE="0.15832603141805462" ORDER="7" O_E="6.16810758885687" SE="0.2431129185982705" STUDY_ID="STD-Stone" TOTAL_1="1036" TOTAL_2="1046" VAR="16.919359789628615" WEIGHT="50.74984109127532"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan">
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-09-09 10:10:06 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>